Amneal Announces Virtual Event to Discuss Initial Data from Pivotal Phase 3 Study of IPX-203 in Patients with Parkinson’s Disease Who Experience Motor Fluctuations
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced that it will host a virtual event for the investment community on Wednesday, August 25, 2021 at 4:30 p.m.
- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced that it will host a virtual event for the investment community on Wednesday, August 25, 2021 at 4:30 p.m.
- A replay will be made available on the companys website for six months following the conclusion of the event.
- IPX-203 is a novel, oral formulation of extended-release CD/LD for patients experiencing motor fluctuations.
- The Company has operations in North America, Asia, and Europe, working together to bring high-quality medicines to patients primarily within the United States.